No. of Recommendations: 11
I used to subscribe to bloodhound, a website that presented backtested strategies, some of which used the Valueline 1700 as their sub-universe. They went out of business after 11/2016 so I didn't update the numbers but you might want to start here. I haven't looked at these since but you might be able to create a usable strategy.
10 stock CAGR 27%
valueline 1700 not otc
12 mo. R&D /sales>=2%
5 yr sales gro>0
beta>=1.25
p>$2
rank by hi gross margin
20% cagr
valueline 1700
price<=$10
inventory/ sales 12 m <=25%
CFPS growth 5 yr>=0
Sales gro 5 hr>= -25%
price>5
rank by 12 mo gross margin high
valueline 1700 not otc
12 mo sales <= 2 bill
FYE declared div<=0
inventory /sales 12 mo <= 12
ROA >= 5
beta<1.25
p>2
Book Value(Reported)/Share Fiscal Quarter End bottom rank
23.9% cagr
valueline 1700 not otc
12 mo sales <= 2 bill
FYE declared div<=0
inventory /sales 12 mo <= 12
ROA >= 5
beta<1.25
p>2
Debt/Capital Fiscal Quarter End. rank high
24%
p>=$4 and NOT NYSE
Sales/Capital Fiscal Year End. Sales expressed as a percentage of total capital. >=150%
rank by high gross margin
38%
mcap >=150 m or 50m
12 mo asset turn>= .5
FYE declared div<= .01 or leave out
inventory /sales 12 mo <= 25%
R&D / sales 12 mo >=2%
beta>= .8
p>2
ROA 12 mo rank high or Cost of Goods Sold/Sales Trailing 12 Months
38%
insider<20%
rank by high sales growth
assets / # of employees >100,000 < 750,000
div per share high
48%
Value Line Financial Strength Fiscal Year End. C++ to B++
49%
insider hold 10% to 30%
rank by sales grow
36%
valueline 1700
not otc
Estimated EBITDA % Current 12 months>= 1 yr ago
( Value Line's estimate for EBITDA margin for the current year)
P/ CF 12 mo>0
p / BV >0
rank by combining various value measures
cagr 41%
valueline 1700 not otc
Standard Deviation Earnings Per Share<= .2
(The standard deviation of the past 12 quarters of Primary Earnings Per Share.)
P/ CF and P/ BK >0
rank by combining various value measures
not nasdaq
current ratio>= .02
div gro 10 yr>0
P>4
cf/ share high rank
54%
sales 12 mo>100m
Net Income Before Discontinued, Non-recurring, and Extraordinary Fiscal Year End>=100mill
(Profit after deduction of all expenses including taxes, and minority interests, but before deduction of preferred dividends paid and accumulated and before any non-recurring, special, and extraordinary items. Reported as of fiscal year end.)
p>2
rank by sales/ share 12 mo high
24%
nasdaq
sales / cap >= 100%
cf/ share <=350
p>8
rank by hi gross maragin
39%
valueline1700 no otc
R&D / sales 12 m >= 2%
gross margin 12 m >=30%
p>5 and mcalp>50
p/ 52 wk high rank low
54%
sales >100 m
Net Income Before Discontinued, Non-recurring, and Extraordinary Fiscal Year End. >100
(Profit after deduction of all expenses including taxes, and minority interests, but before deduction of preferred dividends paid and accumulated and before any non-recurring, special, and extraordinary items. Reported as of fiscal year end.)
rank by sales/ share high
